New hope for myelofibrosis: selinexor trial targets spleen and symptoms

NCT ID NCT04562870

Ongoing Disease control Sponsor: Karyopharm Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase 2 study tests the drug selinexor against standard treatments in 112 people with myelofibrosis who have already tried JAK inhibitors. The main goal is to see if selinexor can shrink the spleen and improve symptoms. Participants are randomly assigned to receive either selinexor or their doctor's choice of therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selinexor
What this could lead to: If successful, selinexor could offer a new treatment option for myelofibrosis patients who have not responded well to standard JAK inhibitor therapy.
What could go wrong: This is a phase 2 trial with only 112 participants, so results may not be definitive. Selinexor may cause side effects like nausea, fatigue, or low blood counts, and it may not prove better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

Affiliated Hospital of Nantong University

Nantong, Jiangsu, 226001, China
Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi

Varese, 21100, Italy
Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti

Latina, 4100, Italy
Centre Hospitalier Universitaire d'Angers (CHU Angers)

Angers, 49933, France
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Illinois Cancer Specialist

Niles, Illinois, 60714, United States
Institut de Cancéro-Hématologie

Brest, Brittany Region, 29609, France
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS

Meldola, Forlì-Cesena, 47014, Italy
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
Pratia Onkologia Katowice

Katowice, 40-519, Poland
Rocky Mountain Cancer Centers, LLP

Aurora, Colorado, 80012, United States
Sir Run Run Shaw Hospital - Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
Suzhou University -The First Affiliated Hospital

Suzhou, Jiangsu, 215007, China
Texas Oncology - Northeast Texas

Tyler, Texas, 75702, United States
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
The Oncology Institute of Hope and Innovation

Pasadena, California, 91105, United States
The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215004, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
University General Hospital "ATTIKON"

Athens, Attica, 12462, Greece
University of Perugia Department of Medicine Hematology Section

Perugia, 6132, Italy
Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica

Florence, 50134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.